Endo International PLC ENDO INTERNATIONAL ORD SHS
Endo International PLC ENDO INTER.../ IE00BJ3V9050 /
0Y5F
|
1/26/2023 3:46:04 PM
|
Chg.
-
|
Volume |
Bid6:00:11 AM |
Ask6:00:11 AM |
Market Capitalization |
Dividend Y. |
P/E Ratio |
|
0.1020USD
|
-
|
500
Turnover: 51 |
-Bid Size: - |
-Ask Size: - |
67.48 mill.USD |
0.00% |
- |
Business description
Endo International plc is a global specialty pharmaceutical company focused on improving patients' lives while creating shareholder value. Endo develops, manufactures, markets and distributes quality branded pharmaceutical and generic pharmaceutical products as well as over-the-counter medications though its operating companies. Endo has global headquarters in Dublin, Ireland, and U.S. headquarters in Malvern, PA.
Management board & Supervisory board
| CEO |
| Blaise Coleman |
| Management board |
| Mark Bradley, Dr. James P. Tursi, George Apostol, M.D., James Papp, Joseph A. Barbarite, Laure Park, Matthew J. Maletta, Patrick Barry, Robert Polke, Ruth Thorpe, Susan Williamson, Tracy Basso |
| Supervisory board |
| Mark G. Barberio, Blaise Coleman, Dr. M. Christine Smith, Dr. Nancy J. Hutson, Jennifer M. Chao, Michael Hyatt, Shane M. Cooke, William P. Montague |
Company data
| Name: |
Endo International Plc. |
| Address: |
First Floor, Minerva House, Simmonscourt Road,Ballsbridge, Dublin 4, Ireland |
| Phone: |
+11-353-1-268-200 |
| Fax: |
- |
| E-mail: |
-
|
| Internet: |
www.endo.com/ |
| Industry: |
Healthcare |
| Sector: |
Pharmaceutical Industry |
| Sub sector: |
Pharmaceuticals |
| End of financial year: |
12/31 |
| Free Float: |
57.10% |
| IPO date: |
- |
Main Shareholders
| Freefloat |
|
57.10% |
| BlackRock Inc. |
|
15.70% |
| The Vanguard Group, Inc. |
|
10.90% |
| Renaissance Technologies LLC |
|
8.40% |
| Paulson & Co., Inc. |
|
7.90% |